Other vaccines containing multiple tumor-associated antigens including MAGE proteins, MART-1/MelanA, and gp100 were tested in a phase I/II trial in patients with advanced melanoma with evidence of clinical activity and durable responses [81]. Here, MLANA is linked to melanoma.